New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).

MLA

Yki-Järvinen, Hannele, et al. “New Insulin Glargine 300 Units/ML versus Glargine 100 Units/ML in People with Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2).” Diabetes Care, vol. 37, no. 12, Dec. 2014, pp. 3235–43. EBSCOhost, https://doi.org/10.2337/dc14-0990.

APA

Yki-Järvinen, H., Bergenstal, R., Ziemen, M., Wardecki, M., Muehlen-Bartmer, I., Boelle, E., & Riddle, M. C. (2014). New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care, 37(12), 3235–3243. https://doi.org/10.2337/dc14-0990

Chicago

Yki-Järvinen, Hannele, Richard Bergenstal, Monika Ziemen, Marek Wardecki, Isabel Muehlen-Bartmer, Emmanuelle Boelle, and Matthew C Riddle. 2014. “New Insulin Glargine 300 Units/ML versus Glargine 100 Units/ML in People with Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2).” Diabetes Care 37 (12): 3235–43. doi:10.2337/dc14-0990.